EU project description
The theme of this collaborative project is development and application of neuroimaging and bioinformatics tools to study lipid metabolism as a common pathogenic link between psychotic disorders and its metabolic co-morbidities. The overall objective is to identify, prioritize and evaluate multi-modal blood and neuroimaging markers with diagnostic potential for prediction and monitoring of psychotic disorders and associated metabolic co-morbidities.
By combining human cohort studies, methodology developments and translational research, we aim to
- optimise a multidisciplinary approach for combining positron emission tomography (PET) and magnetic resonance imaging (MRI) with metabolomics approaches,
- develop a PET-method for exploring endocannabinoid pathways in early psychosis in longitudinal study setting, and
- develop combined PET-MRI biomarker methodology for psychiatric disorders by studying neurotransmitter interactions with multiple PET scan and MRI sequences.
The expected impacts are
- etiopathogenic understanding,
- new validated multi-modal markers for early disease detection and monitoring,
- new tools for the identification of subjects who may benefit from specific treatment
- discovery of new avenues for disease prevention and therapy, and
- new tools and processes for applying brain imaging in personalised medicine.
The consortium brings together clinicians, researchers and industry partners in the domains of psychiatry, neuroimaging, metabolic research, systems biology and bioinformatics.
EU FP7 programme
Grant agreement no: 602478
With the support from the European Commission, METSY has been set up to identify, prioritize and evaluate multi-modal blood and neuroimaging markers for prediction and monitoring of psychotic disorders and its associated metabolic co-morbidities.
Total budget: 5.91 mio Euros
EU contribution: 4.23 mio Euros
Coordinator: Matej Orešič, Turku Centre for Biotechnology